These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38265568)

  • 21. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use.
    Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R
    J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer. Preliminary results.
    Vergine M; Scipioni P; Garritano S; Colangelo M; Di Paolo A; Livadoti G; Maturo A; Monti M
    G Chir; 2013; 34(9-10):254-6. PubMed ID: 24629809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
    Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
    Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
    Dixon JM; Anderson TJ; Miller WR
    Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
    Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival Outcomes of Breast-Conserving Surgery Versus Mastectomy in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis.
    Qin R; Yin L; Wang D; Cao X; Shaibu Z; Wang X; Chen P; Sui D; Qiu X; Liu D
    Technol Cancer Res Treat; 2024; 23():15330338241265030. PubMed ID: 39043051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Endocrine Therapy: Who Benefits Most?
    Grossman J; Ma C; Aft R
    Surg Oncol Clin N Am; 2018 Jan; 27(1):121-140. PubMed ID: 29132556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
    Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
    Man VC; Cheung PS
    Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03).
    Takei H; Suemasu K; Inoue K; Saito T; Okubo K; Koh J; Sato K; Tsuda H; Kurosumi M; Tabei T;
    Breast Cancer Res Treat; 2008 Jan; 107(1):87-94. PubMed ID: 18043897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer.
    Matsunuma R; Watanabe T; Hozumi Y; Koizumi K; Ito Y; Maruyama S; Ogura H; Goto K; Mori H; Sawai N; Shiiya N
    Breast Cancer; 2020 Sep; 27(5):819-827. PubMed ID: 32144735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.